Executive Summary
Today, treatment alternatives for every oncology patient are individually discussed by medical
experts in so-called tumor boards. However, the molecular analysis of each tumors is very complex and the assessment of individual tumor variants time-consuming. Therefore, specialized molecular tumor boards focus also on the analysis and therapy assessment incorporating fine-grained molecular data.
We worked together with subject-matter experts to defined and evaluate a standardized clinical process, designed adequate tool support, and integrated relevant data source for an improved tumor board experience in molecular tumor boards. For example, we applied the scrum board approach, which is well-known from software engineering, to the clinical challenge.
Project Partners
- Highmed Medical Informatics Consortium
- German Cancer Research Center
- National Center for Tumor Diseases
- Charité — University Medicine Berlin
- Hasso Plattner Institute and AnalyzeGenomes.com
Related Content
- Slides of the 2019 Bio Data World congress available
- Slides of the 2019 Clinical Trials Conference available
- Politik schafft endlich Fakten
Sponsors
